OCI-LY1 Cells

OCI-LY1 is a human diffuse large B-cell lymphoma (DLBCL) cell line derived from an adult patient. It belongs to the germinal center B-cell (GCB) subtype of DLBCL, characterized by its molecular signature that mirrors normal germinal center B cells. This classification is supported by gene expression profiling, which has shown that OCI-LY1 clusters with GCB-DLBCLs, a group typically associated with a better prognosis compared to activated B-cell (ABC) DLBCL. The cell line maintains surface expression of B-cell markers and exhibits hallmarks of DLBCL including a high proliferation rate and chromosomal abnormalities consistent with aggressive lymphoma behavior.

OCI-LY1 has been a valuable model in the study of genetic heterogeneity and oncogenic signaling in DLBCL. Genomic studies have identified recurrent mutations in this line, including alterations in genes regulating chromatin remodeling, apoptosis, and B-cell receptor signaling pathways. Notably, OCI-LY1 does not harbor constitutive NF-κB pathway activation, a feature that distinguishes it from ABC-DLBCL cell lines and aligns it with the GCB molecular subtype. This makes it particularly useful for investigating mechanisms of lymphomagenesis and drug responses that are independent of NF-κB signaling. Furthermore, it has been used in immunogenetic studies including HLA typing, which is critical for exploring tumor immunogenicity and neoantigen presentation in the context of cancer immunotherapy.

In culture, OCI-LY1 cells exhibit suspension growth and are amenable to both in vitro and in vivo experimentation, including xenograft studies. They retain clonotypic immunoglobulin rearrangements, confirming their derivation from a single B-cell clone. Their stable growth properties and genetic profile make them a reliable tool for preclinical testing of targeted therapies, particularly those aimed at epigenetic modulators, PI3K pathway inhibitors, and agents inducing DNA damage responses.